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Abstract: Cyclodextrins are used extensively in food, cosmetic, drug and chemical industries to increase aqueous solubility and
stability, and reduce or eliminate the unpleasant taste and smell of many products. Experiments were conducted to examine the
effect of a pre-haemolytic dose of methyl β-cyclodextrin (MBCD) on the osmotic fragility of erythrocytes collected from sheep, cattle
and humans.
Heparinised blood collected from these three species were analysed within 3 h of collection. Erythrocyte suspensions were mixed
with MBCD to give concentrations of 2 mM, 4 mM or 6 mM cyclodextrin. The mixtures were incubated for 30 min at 37 ˚C and
centrifuged. The osmotic fragility of re-suspended erythrocytes was measured.
The incubation of MBCD with the erythrocyte suspensions induced a dose-dependent increase in the osmotic fragility of erythrocytes
obtained from all three species. The beginning of haemolysis in control groups of sheep, cattle and humans occurred at 0.85%,
0.70% and 0.55% NaCl, respectively. However, haemolysis in the MBCD-treated groups began earlier than this in all the three
species studied. The osmotic fragility of erythrocytes was significantly higher at NaCl concentrations of 0.70% (P > 0.01), 0.75%
(P > 0.001) and 0.80% (P > 0.001) in sheep; 0.55% (P > 0.01), 0.60% (P > 0.001) and 0.65% (P > 0.01) in cattle; and 0.40%
(P > 0.01), 0.45% (P > 0.001) and 0.50% (P > 0.01) in humans than in the controls.
In conclusion, these results indicate that a pre-haemolytic dose of MBCD may also induce membrane disruption which elicits removal
of membrane components from erythrocytes.
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‹nek, Koyun ve ‹nsan Eritrositi Ozmotik Fajilitesi Üzerine Metil-β-Siklodextrinin
Karfl›laflt›rmal› Etkisi
Özet: Siklodekstrinler g›da, kozmetik, ilaç ve kimya sanayiinde kullan›m alan› bulan baz› etken maddelerin çözünürlü¤ünü ve
stabilitesini art›rmak, etken maddelerde bulunan baz› istenmeyen tat ve kokular› maskelemek için yayg›n olarak kullan›lmaktad›r. Bu
çal›flmada pre-hemolitik dozda kullan›lan metil-β-siklodekstrinin (MBCD) koyun, inek ve insan eritrositi ozmotik frajilitesi üzerine
etkisi araflt›r›ld›.
Bu üç türden elde edilen heparinli kan, al›m› takiben üç saat içinde analiz edildi. Eritrositlerden 2, 4 veya 6 mM MBCD içerecek flekilde
süspansiyonlar haz›rland›. Kar›fl›m 37 ˚C ›s›da 30 dk inkübe edildikten sonra santrifüj edildi. Tekrar suland›r›lan eritrositlerin ozmotik
frajiliteleri ölçüldü
Her üç türde de eritrosit süspansiyonu ile inkübe edilen MBCD, eritrositlerin ozmotik frajilitesinde doza paralel olarak artan bir
ozmotik frajiliteye yol açt›. Hemoliz bafllang›c› koyun, inek ve insan kontrol gruplar›nda s›ras› ile %0,85, %0,70 ve %0,55 NaCl
olarak bulundu. Bunun aksine MBCD uygulanan gruplar›n hepsinde de hemoliz, bundan çok daha erken bafllad›. Eritrositlerin ozmotik
frajilitesi NaCl solüsyonunun %0.70 (P>0.01), %0.75 (P>0.001) ve %0.80 (P>0.001) konsantrasyonlar›nda koyunda, %0.55
(P>0.01), %0.60 (P>0.001) ve %0.65 (P>0.01) konsantrasyonlar›nda inekte ve %0.40 (P>0.01), %0.45 (P>0.001) ve %0.50
(P>0.01) konsantrasyonlar›nda ise insanda kontrol gruplar›nkinden daha fazla bulundu.
Sonuç olarak; pre-hemolitik dozda kullan›lan siklodextrine ba¤l› olarak eritrosit frajilitesinde meydana gelen art›fl, bu
makromolekülün düflük dozlar›n›n dahi membran komponentlerini uzaklaflt›rarak, eritrosit membran dayan›kl›l›¤›n› azaltt›¤›na iflaret
etmektedir.
Anahtar Sözcükler: Siklodekstrin, eritrosit, ozmotik frajilite, koyun, inek, insan

383

A Comparison of the Effect of Methyl-β-Cyclodextrin on the Osmotic Fragility of Ovine, Bovine and Human Erythrocytes

Introduction
Cyclodextrins are cyclic oligosaccharides consisting of
6, 7, or 8 glucopyranose units, usually referred to as α-,
β- and γ-cyclodextrins, respectively. They are used in
food, cosmetic, drug and chemical industries to increase
aqueous solubility and stability, and reduce or eliminate
the unpleasant taste and smell of a range of products (14). Hydrophobic guest molecules such as cholesterol can
be incorporated into the cavity of cyclodextrin by
displacing water. The resulting complex is water-soluble,
although the guest molecule can be released relatively
easily (5). Cavity size is the major determinant as to
which cyclodextrin is used in complexation. αCyclodextrins have small cavities which are not capable of
accepting many molecules. γ-Cyclodextrins have much
larger cavities that allow many molecules to be
incorporated. However, the cavity diameter of βcyclodextrins is well-suited for use with many
compounds. Therefore, β-cyclodextrins are most
commonly used as a complexing agent (6).
It is well known that β-cyclodextrin in particular has
very poor aqueous solubility. Thus, natural cyclodextrins
must be modified chemically for various applications.
Among the chemically modified cyclodextrins, methylated
cyclodextrins are commonly used as complexing agents
(7). Therefore, methyl-β-cyclodextrin (MBCD) was
chosen by us to study.
Previous studies have demonstrated that cyclodextrins
are very efficient at stimulating the removal of
cholesterol, phospholipids and proteins from a variety of
cells in culture (6,8,9). It has been suggested that the
extraction of proteins by cyclodextrin may really be an
extrusion process in which proteins are shed from the
membrane into the aqueous phase through an erosion of
the lipid regions of the membrane (10). Thus,
cyclodextrins are used as effective extracellular
cholesterol acceptors to monitor the efflux of cholesterol
through the plasma membrane of living cells (11-14)
The adverse effect of cyclodextrin on human
erythrocytes has been thoroughly studied. Erythrocyte
membranes are composed of proteins associated with a
lipid bilayer matrix. Their fractions consist of 43% lipids,
49% proteins and 8% carbohydrates; 25% of total
membrane lipids are cholesterol (15). Methylated βcyclodextrins were found to induce haemolysis at
relatively high concentrations (6). The haemolytic activity
of cyclodextrin has already been attributed to an
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extraction of lipids from the erythrocyte membrane
(10,16). However, pre-haemolytic concentrations of βcyclodextrins were demonstrated to cause shape changes
in human erythrocytes (10,17). Thus, the present work
was designed to test the effect of pre-haemolytic
concentrations of cyclodextrin on erythrocyte osmotic
fragility.
Although the effects of cyclodextrin on the osmotic
fragility of erythrocytes have not yet been investigated,
considerable research has been done on osmotic fragility
itself (18-20). These studies postulated that marked
species variations exist in erythrocyte susceptibility to
haemolysis in hypotonic saline. This susceptibility is
related in part to red cell size, since increasing fragility
correlates with decreasing cell volume (21). Therefore,
three species were used to determine the effect of
erythrocyte sizes on cyclodextrin-induced haemolysis.
Normal red cells are biconcave discs having a mean
diameter of approximately 4.5 µm, 5.8 µm and 8 µm in
ovine, bovine and human blood, respectively (21,22).
The first objective of this study was to determine the
effectiveness of a pre-haemolytic dose of MBCD on the
osmotic fragility of ovine, bovine and human
erythrocytes. The second objective was to examine the
effect of erythrocyte size on MBCD-induced hemolysis.
The third objective was to assess the effect of time on
MBCD-induced erythrocyte osmotic fragility.

Materials and Methods
Preparation of erythrocyte suspensions
Methyl-β-cyclodextrin was purchased from Sigma.
Blood samples from eight sheep, seven cattle and seven
humans were mixed with heparin and analysed within 3 h
of collection. The blood samples were centrifuged at
1500 x g for 10 min to separate the plasma and
erythrocytes. The retrieved erythrocytes were washed
three times with the isotonic phosphate buffered saline
(PBS) (154 mM NaCl, 10 mM sodium phosphate, pH
7.4). The buffy coat was carefully removed with each
wash. After final washing, the packed cells were resuspended in PBS to give a haematocrit value of 33%.
Finally, cell suspensions were mixed with MBCD to give 2
mM, 4 mM and 6 mM cyclodextrin concentrations. The
mixtures were incubated for 30 min at 37 ˚C and
centrifuged at 1500 x g for 10 min. The osmotic fragility
assays of re-suspended erythrocytes were performed in
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PBS containing increasing concentrations of NaCl. Bovine
erythrocytes were also incubated with 6 mM MBCD for 1,
5, 10, 15, 20 or 30 min to assess the effect of time on
the cyclodextrin-induced fragility of the erythrocytes.
Hemolysis was measured at the NaCl concentration of
0.6%.
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Statistical analysis
Different treatments were assessed by analysis of
variance (ANOVA) and Duncan’s multiple range test.
Significance was defined as P < 0.05. All statistical
analyses were carried out using the Statistical Package for
Social Sciences (SPSS). All results are reported as means
± S.E.M.
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The osmotic fragility assays were performed as
described by Parpart et al. (23) in phosphate buffer
solutions (10 mM sodium phosphate, pH 7.4) containing
various concentrations of NaCl. Optical density was read
at 540 nm on a UV-1280 Shimadzu Spectrophotometer
(Shimadzu Corporation, Australia). The percentage of
haemolysis in each concentration of NaCl was calculated,
assuming 100% haemolysis in distilled water. The results
were expressed as % haemolysis.
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Results
The effects of MBCD on osmotic fragility,
evaluated from the curves of haemolysis as a function
of NaCl concentration, are shown in Figure 1.
Incubation of cyclodextrin with the erythrocyte
suspensions induced a dose-dependent increase in the
osmotic fragility of erythrocytes obtained from sheep,
cattle and humans. The beginning of haemolysis in
control groups of sheep, cattle and humans occurred
at 0.85%, 0.70% and 0.55% NaCl, respectively.
However, haemolysis in the MBCD-treated groups
started earlier than this in all the three species
studied. The osmotic fragility of erythrocytes was
significantly higher at NaCl concentrations of 0.70%
(P > 0.01), 0.75% (P > 0.001) and 0.80% (P >
0.001) in sheep; 0.55% (P > 0.01), 0.60% (P >
0.001) and 0.65% (P > 0.01) in cattle; and 0.40% (P
> 0.01), 0.45% (P > 0.001) and 0.50% (P > 0.01)
in humans than in the controls.
The effects of time on the MBCD-induced fragility of
bovine erythrocytes, evaluated from the haemolysis
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Figure 1.

0.4

Effect of MBCD on the osmotic fragility of ovine (A), bovine
(B) and human (C) erythrocytes. Erythrocytes were
incubated without (■) or with 2 mM (●), 4 mM (▲) or 6
mM (▼) MBCD. Results were expressed as a percentage of
total haemolysis.

curve as a function of 0.6% NaCl concentration, are
shown in Figure 2. The incubation of 6 mM MBCD with
the erythrocyte suspensions was induced to very rapid
haemolysis. Over 70% of the haemolysis occurred
within 5 min, and maximum haemolysis occurred within
20 min.
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Figure 2.

Changes in erythrocyte fragility (%)
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Effect of time on MBCD-induced
fragility of bovine erythrocytes.
Erythrocytes were incubated with 6
mM MBCD for 1, 5, 10, 15, 20 or 30
min. Haemolysis was measured at the
NaCl concentration of 0.6%.
Haemolysis prior to treatment and the
maximum haemolysis after treatment
were assumed to be 0% and 100%
respectively. Results are the means ±
SEM of four independent experiments.
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Discussion
The present study has examined the hypothesis that
higher concentrations of cyclodextrin will increase
erythrocyte osmotic fragility. It is reported that high
concentrations of cyclodextrins induce haemolysis in
erythrocytes (16,24,25). Studies with isolated
erythrocytes, which have no cell organelles, may provide
a simple and reliable measure for cyclodextrin cytotoxicity
because the interaction of cyclodextrins with plasma
membranes must be the initial step for cell damage. Since
marked species variation exists in the mechanical fragility
of ovine, bovine and human erythrocytes in hypotonic
saline (20,26) and the susceptibility is related in part to
red cell size (21), the blood collected from different
species was, therefore, used in the present study. Thus,
the effect of pre-haemolytic doses of MBCD on the
osmotic fragility of ovine, bovine and human erythrocytes
was investigated.

28 30 32

correlation between the haemolytic activity of several
cyclodextrins and their capacity to remove cholesterol
from different cell membranes (5,6,25,27). It is,
therefore, possible that the extraction of membrane
compounds from the erythrocyte by cyclodextrin may
result in an increase in membrane fluidity, which would
induce membrane invagination through a loss of bending
resistance and consequently lead to the lysis of
erythrocytes.

The incubation of MBCD with the erythrocyte
suspensions induced a dose-dependent increase in the
osmotic fragility of erythrocytes obtained from all three
species (Figure 1). This observation indicates that low
concentrations of cyclodextrins also induced erythrocyte
membrane damage. It was previously shown that prehaemolytic concentrations of β-cyclodextrins caused
shape changes in human erythrocytes (5,10,17).

The haemolysis induced by MBCD on erythrocytes
suspended in 0.6% NaCl was studied as a function of
incubation time in erythrocyte suspension obtained from
bovine samples. As shown in Figure 2, the incubation of
red cells with 6 mM MBCD at 37 ºC results in timedependent haemolysis. More than 70% of haemolysis
occurred in the first 5 min of incubation. This observation
indicates that cyclodextrin-induced damage to erythrocyte
membranes is a very rapid process. This observation is
supported by the fact that when labelled human
erythrocytes were exposed to a solution of β3
cyclodextrins, part of the ( H) cholesterol was extracted
from erythrocytes into the supernatant within a few
minutes (10). They also reported that the concentrations
of cholesterol extracted from erythrocytes into the
aqueous phase increased with progressively higher
concentrations of β-cyclodextrins.

The haemolytic activity of cyclodextrins correlates
with their inclusion ability toward membrane lipids rather
than their surface activity or intrinsic solubility. This
hypothesis is supported by the fact that there is a positive

In conclusion, the results from the present study
indicate that a pre-haemolytic dose of MBCD also induced
the membrane disruption which elicited removal of
membrane components from erythrocytes.
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